MINNETONKA, Minnesota, August 19, 2026, 12:28 EDT — UnitedHealth Group NYSE:UNH shares were last quoted at $390.35 at 11:58 EDT, off 0.91% with roughly 1.4 million shares changing hands. The New York Stock Exchange was open for trading.
- UNH fell 4.11% from its August 7 close, as SPY declined approximately 0.4%.
- The derivative lawsuit does not specify an amount of damages, and its claims have not been proven.
- FactSet’s median price target of $490 suggests a 25.5% potential gain from the market-data cut.
Renewed interest from investors followed a stock-focused report released on August 18. The amended complaint at the center of the matter was submitted on August 7, with court records indicating no subsequent decision on the merits.
UNH shares traded 4.11% lower than their August 7 closing price of $407.08. In comparison, the SPDR S&P 500 ETF Trust NYSEARCA:SPY fell by roughly 0.4% in the same interval, putting UnitedHealth around 3.7 percentage points behind the benchmark.
| Benchmark since August 7 filing | August 7 close | August 19, 11:58 EDT | Change |
|---|---|---|---|
| UnitedHealth | $407.08 | $390.35 | -4.11% |
| SPY | $773.26 | About $770.30 | Roughly -0.4% |
| UNH relative performance | — | — | Near -3.7 percentage points |
The relative decrease reflects a market observation, not evidence of causation. Shares of insurers are also influenced by medical utilization, Medicare reimbursement policy, changes in earnings estimates, and overall risk tolerance.
Shareholder lawsuit prompts governance concerns
The amended complaint for McCollum v. Witty, identified as case 0:24-cv-02643-JMB-JFD, was submitted in the U.S. District Court for Minnesota as Document 71. The Employees’ Retirement System of Rhode Island and Länsförsäkringar Fondförvaltning AB are among the plaintiffs.
The complaint accuses the company of lapses in Medicare Advantage coding, decisions on coverage, privacy and cybersecurity measures at Change Healthcare, insider stock sales, and share buybacks. It further claims an internal review identified no less than $200 million in Medicare diagnoses or claims lacking support prior to the suspension of the program. The allegations have not been ruled upon.
The derivative suit aims to secure recovery for UnitedHealth and implement governance changes, but does not specify an amount of damages. UnitedHealth declined to comment on the lawsuit, Claims Journal reported. In a statement released in July 2025, UnitedHealth said it remained confident in its practices and was cooperating with official civil and criminal inquiries from the Department of Justice.
UnitedHealth’s most recent Form 10-Q reports that government probes, subpoenas and investigations are ongoing. Some relate to adherence with Medicare risk-adjustment coding rules. CMS and OIG audits may result in retrospective payment changes, and losses tied to various legal issues remain unquantifiable.
The regulatory outlook is varied. CMS has approved an average boost of 2.48%, totaling over $13 billion, in 2027 Medicare Advantage payouts. Factoring in projected risk-score trends, that figure climbs to 4.98%. CMS will continue to leave out most diagnoses found in unlinked chart-review data.
The Change Healthcare breach continues to be included in the risk file. HHS stated that, as of July 31, 2025, Change Healthcare had reported nearly 192.7 million impacted individuals. UnitedHealth’s most recent annual report posted a $799 million boost to reserves allocated for anticipated uncollected provider loans and related balances linked to the event.
Operating rebound reflected in second-quarter earnings
The lingering legal issues stand in contrast to improved operational performance. UnitedHealth’s second-quarter report indicated a 55.2% increase in operating earnings and a 61.0% jump in attributable net income. The medical-care ratio was lower by 270 basis points. Chief Executive Stephen Hemsley said the figures and projections showed “continuing progress” in simplifying operations.
| Q2 metric | 2026 | 2025 | Year-over-year change |
|---|---|---|---|
| Revenue | $112.032 billion | $111.616 billion | up 0.37% |
| Operating earnings | $7.991 billion | $5.150 billion | increased by 55.2% |
| Attributable net income | $5.484 billion | $3.406 billion | rose 61.0% |
| Adjusted EPS | $6.38 | $4.08 | climbed 56.4% |
| Medical-care ratio | 86.7% | 89.4% | decreased 270 basis points |
| UnitedHealthcare operating margin | 4.6% | 2.4% | improved by 220 basis points |
Management increased its 2026 guidance, projecting adjusted EPS between $19.50 and $20.00. The company forecasts operating earnings to exceed $25.45 billion, operating cash flow around $24 billion, and a minimum of $5 billion allocated to share buybacks.
The midpoint of adjusted EPS guidance at $390.35 suggests a multiple of around 19.8 times. In comparison, the trailing multiple stood at approximately 25.2 times. This valuation reflects expectations for substantial earnings improvement over the past 12 months.
Market lags behind Wall Street targets
The WSJ/FactSet consensus rates the stock as Overweight, with 19 analysts assigning a Buy, four giving Overweight, six Hold and one Underweight ratings. The median target stands at $490, suggesting a potential 25.5% gain, while the average target of $481.52 points to a 23.4% increase. Targets represent analyst opinions and are not assured results.
| Date | Broker | Action | Rating | Price target |
|---|---|---|---|---|
| July 21 | JPMorgan | Increased | Overweight | $466 to $516 |
| July 20 | Wells Fargo | Increased | Overweight | $485 to $526 |
| July 17 | Morgan Stanley | Increased | Overweight | $468 to $529 |
| July 17 | Goldman Sachs | Increased | Buy | $435 to $490 |
| July 17 | Oppenheimer | Increased | Outperform | $420 to $500 |
| July 17 | Bank of America | Increased | Buy | $475 to $512 |
| July 17 | UBS | Increased | Buy | $460 to $490 |
| July 16 | Baird | Upgraded | Underperform to Neutral | $287 to $453 |
Valuations among peers continue to vary. UnitedHealth’s guidance multiple is higher than a number of diversified managed-care peers, yet it is beneath its own trailing multiple.
| Company | Price | Day change | TTM P/E | 2026 guidance multiple |
|---|---|---|---|---|
| UnitedHealth NYSE:UNH | $390.35 | -0.91% | 25.06x | 19.8x |
| Elevance Health (NYSE:ELV) | $399.74 | +0.37% | 17.70x | No more than 14.8x |
| CVS Health (NYSE:CVS) | $94.02 | -0.94% | 24.81x | 11.8x |
| The Cigna Group (NYSE:CI) | $279.56 | +0.38% | 11.57x | No more than 9.2x |
| Humana (NYSE:HUM) | $377.07 | -1.29% | 35.61x | Not above 41.9x |
Risks: The complaint outlines allegations rather than conclusions. Impacts hinge on decisions by the courts, DOJ and CMS results, available remedies, medical expenses, and the sustainability of margin recovery at UnitedHealthcare and Optum. Analyst targets may shift rapidly.
Currently, UNH faces two opposing forces: a clear governance overhang and signs of an operational rebound that led to widespread target hikes. The outcome will hinge more on future court decisions, regulatory actions and ensuing performance than the present filing.
Related articles: NYSE:UNH
Governance · Medicare · Cybersecurity
UnitedHealth risk and recovery dashboard
UNH is in focus after a derivative complaint alleged governance failures involving Medicare Advantage coding and the Change Healthcare breach. Any effect depends on court and regulatory outcomes. The allegations have not been adjudicated.
Market performance since filing
Shareholder case
Filed August 7 in the U.S. District Court for Minnesota. No damages amount is stated.
Q2 operating recovery
Change Healthcare tail
Analyst target range
Regulatory cross-currents
Payment tailwind
+2.48% / >$13BCMS's final average 2027 Medicare Advantage payment increase. With estimated risk-score trend, it is 4.98%.
Coding control
Unlinked records limitedCMS will generally exclude diagnoses from unlinked chart reviews. UNH's 10-Q says coding reviews remain active.
Recent broker actions
| Date | Broker | Action | Rating | Target |
|---|---|---|---|---|
| Jul 21 | JPMorgan | Raised | Overweight | $516 |
| Jul 20 | Wells Fargo | Raised | Overweight | $526 |
| Jul 17 | Morgan Stanley | Raised | Overweight | $529 |
| Jul 17 | Goldman Sachs | Raised | Buy | $490 |
| Jul 17 | Oppenheimer | Raised | Outperform | $500 |
| Jul 17 | Bank of America | Raised | Buy | $512 |
| Jul 17 | UBS | Raised | Buy | $490 |
| Jul 16 | Baird | Upgrade | Neutral | $453 |
Managed-care valuation snapshot
| Company | Price | Day | TTM P/E | 2026 guide multiple |
|---|---|---|---|---|
| UnitedHealth (NYSE:UNH) | $390.35 | -0.91% | 25.06x | 19.8x |
| Elevance (NYSE:ELV) | $399.74 | +0.37% | 17.70x | ≤14.8x |
| CVS (NYSE:CVS) | $94.02 | -0.94% | 24.81x | 11.8x |
| Cigna (NYSE:CI) | $279.56 | +0.38% | 11.57x | ≤9.2x |
| Humana (NYSE:HUM) | $377.07 | -1.29% | 35.61x | ≤41.9x |
Investor read-through
Recovery case
Q2 operating earnings rose 55%, MCR improved 270 bp and guidance increased. Durable UnitedHealthcare and Optum margin gains would support the lower forward multiple.
Risk case
The derivative allegations, DOJ and CMS reviews, Change Healthcare liabilities and renewed medical-cost pressure could weigh on expectations or sentiment.
